The peptide drug conjugates market is projected to grow from USD 1,240.0 million in 2025 to USD 7,677.8 million by 2035, at a CAGR of 20.0%. Lutetium will dominate with a 38.6% market share, while therapeutic peptide drug conjugates will lead the type segment with a 63.1% share.